AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novel Coronavirus Treatment

1,047.495

-3.557-0.34%

Number of Gainers:10

Number of Losers:7

Number of Flat:15

PE:- -

High:1,056.556

Open:1,051.064

Low:1,044.684

Close:1,051.051

Loading ...

Zoono Group Ltd - Improved Sales Revenues Expected in Q4 FY25 and Q1 FY26

THOMSON REUTERS

Coles - Qtrly Total Group Sales Revenue a$10,379 Mln

THOMSON REUTERS

Coles Group Ltd - in Early Part of Q4, Supermarkets Sales Growth Has Remained Broadly in Line With Q3

THOMSON REUTERS

How to turn $100 a week into $500,000 with ASX shares

This ASX medical device company has a Trump tariff exemption

Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy

MT Newswires Live

BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness Plans

CSL Ltd - CSL Seqirus Signs Agreement With the European Commission to Support Pandemic Preparedness Plans

THOMSON REUTERS

Brokers tip 4 ASX 200 healthcare shares to buy now

Lark Distilling Co Ltd-Proposed Issue of Securities - Lrk

THOMSON REUTERS

Harris Technology Group - No Impact on Revenue From United States Tariffs Expected

THOMSON REUTERS

Harris Technology - Q3 FY25 Sales of a$3.3M

THOMSON REUTERS

3 blue chip ASX dividend stocks to buy and hold forever

BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy

CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy

THOMSON REUTERS

ResMed's U.S. Manufacturing Likely to Boost Margins -- Market Talk

BRIEF-Dimerix Seeks Trading Halt

IDT Australia Ltd - No Impact on IDT Demand From Global Tariffs

THOMSON REUTERS

IDT Australia Ltd - Quarterly Revenue Jumps 30% to a$4.1 Million

THOMSON REUTERS

Mesoblast Appoints Corporate Finance Leader Lyn Cobley to Board

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7501/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":1047.4948,"timestamp":1746683999937,"preClose":1051.0513,"halted":0,"volume":31215000,"delay":0,"changeRate":-0.003384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-3.556519,"latestTime":"05-08 16:00:00 AEST","open":1051.0642,"high":1056.5564,"low":1044.6836,"amount":411429858,"amplitude":0.011296,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746748800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746662400000,1746684000000]],"turnoverRate":0.002207,"increases":10,"decrements":8,"flats":15,"marketCap":270221318999.5,"floatMarketCap":218242656606.08594},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":1056.5564,"amplitude":0.011296,"preClose":1051.0513,"low":1044.6836,"latestPrice":1047.4948,"volume":31215000,"delay":0,"open":1051.0642,"prevYearClose":1117.913,"prevWeekClose":1079.952,"prevMonthClose":1052.524,"prevQuarterClose":1021.93,"fiveDayClose":1063.019,"twentyDayClose":1022.963,"sixtyDayClose":1081.441,"secType":"PLATE","market":"AU","turnoverRate":0.002207,"marketCap":270221318999.5,"floatMarketCap":218242656606.08594,"timestamp":1746683999937,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":10,"down":7,"flat":15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531915712","title":"Zoono Group Ltd - Improved Sales Revenues Expected in Q4 FY25 and Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2531915712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531915712?lang=en_us&edition=fundamental","pubTime":"2025-04-30 07:17","pubTimestamp":1745968638,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R725D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","ZNO.AU","BK7036"],"gpt_icon":0},{"id":"2531711364","title":"Coles - Qtrly Total Group Sales Revenue a$10,379 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2531711364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531711364?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:43","pubTimestamp":1745966590,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nPLX09113F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7082","COL.AU","BK7040"],"gpt_icon":0},{"id":"2531384711","title":"Coles Group Ltd - in Early Part of Q4, Supermarkets Sales Growth Has Remained Broadly in Line With Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2531384711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531384711?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:42","pubTimestamp":1745966553,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R727L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7082","COL.AU","BK7040"],"gpt_icon":0},{"id":"2531071038","title":"How to turn $100 a week into $500,000 with ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2531071038","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531071038?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:15","pubTimestamp":1745964914,"startTime":"0","endTime":"0","summary":"Investing can seem daunting at first — especially if you're starting small. But here's the good news: you don't need a huge salary, a stock-picking superpower, or perfect timing to build serious wealt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/30/how-to-turn-100-a-week-into-500000-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WTC.AU","IVV.AU","VGS.AU","BK7016","BK7007","BK7508","BK7503","WES.AU","BK7067","BK7041","BK7501","BK7153","CSL.AU","BK7511","RMD.AU"],"gpt_icon":0},{"id":"2531716526","title":"This ASX medical device company has a Trump tariff exemption","url":"https://stock-news.laohu8.com/highlight/detail?id=2531716526","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531716526?lang=en_us&edition=fundamental","pubTime":"2025-04-30 06:01","pubTimestamp":1745964084,"startTime":"0","endTime":"0","summary":"It seems brokers are bullish on this blue-chip stock, with multiple brokers placing attractive price targets on the stock thanks to the tariff exemption and strong financials. At the time of writing, shares are trading at $36.75 each. Macquarie has a price target $48.00, indicating a 30% upside. Analysts at Goldman Sachs have retained their conviction buy rating on ResMed shares with an improved price target of $49.30.This was also influenced by the tariff exemption.  Jed Richards from Shaw and Partners says Resmed is a buy. Richards said: On April 24, ResMed posted an 8 per cent increase in revenue in the third quarter of fiscal year 2025. The gross margin improved 140 basis points to 59.3 per cent. Income from operations increased 14 per cent. ResMed's innovative products and steady revenue growth make it a solid investment. Bell Potter has a $43.31 price target.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/30/this-asx-medical-device-company-has-a-trump-tariff-exemption/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","XJO.AU","BK7007","BK7501","XKO.AU","RMD.AU"],"gpt_icon":0},{"id":"2531512517","title":"Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531512517","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531512517?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:51","pubTimestamp":1745938294,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) and CSL Vifor said Tuesday that the European Commission has converted the conditional marketing approval of Filspari into a standard marketing authorization for the treatme","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","CSL","SG9999004303.SGD","BK7067","LU1169590202.USD","LU0728928796.USD","BK4139","BK4156","TVTX","LU1169589451.USD","BK4086","CSL.AU","BK7511","SGXZ23171101.USD","BK7501"],"gpt_icon":0},{"id":"2531769785","title":"BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2531769785","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531769785?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:58","pubTimestamp":1745924321,"startTime":"0","endTime":"0","summary":"BRIEF-Csl Seqirus Signs Agreement With The European Commission To Support Pandemic Preparedness PlansApril 29  - CSL Ltd CSL.AX:CSL SEQIRUS SIGNS  AGREEMENT WITH THE EUROPEAN COMMISSION TO SUPPORT PANDEMIC PREPAREDNESS PLANSFurther company coverage: CSL.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R70YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7501","BK7508","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2531120074","title":"CSL Ltd - CSL Seqirus Signs  Agreement With the European Commission to Support Pandemic Preparedness Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2531120074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531120074?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:30","pubTimestamp":1745922653,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R70YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CSL.AU","BK7508","BK7501","BK7511"],"gpt_icon":0},{"id":"2531227449","title":"Brokers tip 4 ASX 200 healthcare shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2531227449","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531227449?lang=en_us&edition=fundamental","pubTime":"2025-04-29 15:05","pubTimestamp":1745910347,"startTime":"0","endTime":"0","summary":"ASX 200 healthcare shares finished in the green on Tuesday, with the S&P/ASX 200 Health Care Index  lifting 0.61%.  Healthcare is seen as a defensive sector.  In today's turbulent market, perhaps you might be looking for buying opportunities?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/brokers-tip-4-asx-200-healthcare-shares-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7501","BK7508","BK7509","BK7511","HLS.AU","CSL.AU","TLX.AU","BK7124","BK7007","RMD.AU"],"gpt_icon":0},{"id":"2531422945","title":"Lark Distilling Co Ltd-Proposed Issue of Securities - Lrk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531422945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531422945?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:39","pubTimestamp":1745908797,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUE5LLCMT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRK.AU","BK7097","BK7501"],"gpt_icon":0},{"id":"2531522997","title":"Harris Technology Group - No Impact on Revenue From United States Tariffs Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2531522997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531522997?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:37","pubTimestamp":1745908668,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7049","HT8.AU","BK7001"],"gpt_icon":0},{"id":"2531229929","title":"Harris Technology - Q3 FY25 Sales of a$3.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2531229929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531229929?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:37","pubTimestamp":1745908668,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62GN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HT8.AU","BK7049","BK7501","BK7001"],"gpt_icon":0},{"id":"2531750525","title":"3 blue chip ASX dividend stocks to buy and hold forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2531750525","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531750525?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:08","pubTimestamp":1745906914,"startTime":"0","endTime":"0","summary":"When it comes to building a resilient, long-term investment portfolio, blue chip ASX dividend stocks are hard to beat. These are the companies with strong balance sheets, reliable cash flows, and a track record of rewarding shareholders through good times and bad. They provide the rare combination of steady income and capital stability — making them ideal for investors who want to grow their wealth steadily without sleepless nights. But which blue chips would make good buy and hold picks for income investors?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/3-blue-chip-asx-dividend-stocks-to-buy-and-hold-forever/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2089284900.SGD","LU0267386448.USD","LU1668664300.SGD","LU2089283258.USD","LU0912757837.SGD","BK7082","LU0098860793.USD","LU1732800096.USD","XKO.AU","LU1162221912.USD","BK7511","LU0106831901.USD","BK7040","LU1732799900.SGD","XJO.AU","BK4127","LU1363072403.SGD","LU1720051017.SGD","LU0314104364.USD","LU0320765646.SGD","LU2028103732.USD","LU0225283273.USD","BK4504","LU2023251221.USD","LU2111349929.HKD","LU1989772923.USD","XAO.AU","MQG.AU","LU1989772840.SGD","BK4516","LU2271345857.HKD","LU2347655156.SGD","BK4534","COL.AU","LU0006306889.USD","IE00BZ1G4Q59.USD","BK7042","BK7501","LU0158827948.USD","LU0106261372.USD","LU0795875169.SGD","TLS.AU","LU1720051108.HKD","LU1074936037.SGD","LU2357305700.SGD","BK4585","BK4581","BK4588","BK7046","LU0795875086.SGD"],"gpt_icon":0},{"id":"2531225933","title":"BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari® In Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531225933","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531225933?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:04","pubTimestamp":1745906694,"startTime":"0","endTime":"0","summary":"BRIEF-CSL Vifor And Travere Therapeutics Announce Standard EU Approval For Filspari In Iga NephropathyApril 29 (Reuters) - CSL Ltd CSL.AX:CSL VIFOR AND TRAVERE THERAPEUTICS ANNOUNCE STANDARD EU APPROV","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139","BK7067","BK7511","BK7501","BK7508","CSL.AU"],"gpt_icon":0},{"id":"2531225879","title":"CSL Vifor and Travere Therapeutics Announce Standard EU Approval for Filspari® in Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531225879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531225879?lang=en_us&edition=fundamental","pubTime":"2025-04-29 14:01","pubTimestamp":1745906478,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","TVTX","CSL.AU","BK4139","BK7511","BK7067","BK7508"],"gpt_icon":0},{"id":"2531243161","title":"ResMed's U.S. Manufacturing Likely to Boost Margins -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2531243161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531243161?lang=en_us&edition=fundamental","pubTime":"2025-04-29 11:36","pubTimestamp":1745897760,"startTime":"0","endTime":"0","summary":"0336 GMT - ResMed's expanded U.S. manufacturing footprint is seen by Goldman Sachs analysts as likely to further assist strong gross margin accretion at the breath-tech manufacturer. A 70bp expansion in 3Q gross margin was key to ResMed's stronger-than-expected profit for the period, they say. Keeping a buy rating on the stock, the analysts tell clients in a note that margin accretion to date reflects operating leverage from manufacturing capacity expansion, discipline on labor costs, and the optimization of raw materials. GS lifts its target price by 5.1% to A$49.30. Shares are down 0.7% at A$36.68. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004086264.USD","IE00B19Z3581.USD","BK4516","LU2237443895.HKD","BK4082","LU0096364046.USD","LU1868837136.USD","LU1868836914.USD","IE00B19Z3B42.SGD","LU2237443465.HKD","IE00BFXG1179.USD","BK4550","BK4567","LU0170899867.USD","LU2471134952.CNY","BK7501","LU1668664300.SGD","LU2237443549.SGD","RMD","LU1868836757.USD","IE0004091025.USD","LU2750360641.GBP","LU2471134523.USD","BK4585","IE0002270589.USD","LU0061475181.USD","BK4127","LU2177674079.SGD","BK4548","LU0251131958.USD","LU2237438978.USD","LU1791807156.HKD","LU2008162690.USD","BK7007","LU0742534661.SGD","LU2750360997.AUD","LU2237443978.SGD","IE0034235188.USD","LU0048573561.USD","LU2471134879.HKD","RMD.AU","LU2237443622.USD","BK4504","BK4552","LU0106831901.USD","LU1868836591.USD","LU0251142724.SGD","LU1868837300.USD","BK4533","BK4588"],"gpt_icon":0},{"id":"2531319216","title":"BRIEF-Dimerix Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2531319216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531319216?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:44","pubTimestamp":1745891050,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Seeks Trading HaltApril 29 (Reuters) - Dimerix Ltd DXB.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON LICENSING AGREEMENTFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2531914692","title":"IDT Australia Ltd - No Impact on IDT Demand From Global Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2531914692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531914692?lang=en_us&edition=fundamental","pubTime":"2025-04-29 08:04","pubTimestamp":1745885092,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62DK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IDT.AU","BK7501","BK7096"],"gpt_icon":0},{"id":"2531464291","title":"IDT Australia Ltd - Quarterly Revenue Jumps 30% to a$4.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2531464291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531464291?lang=en_us&edition=fundamental","pubTime":"2025-04-29 08:04","pubTimestamp":1745885092,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7501","IDT.AU"],"gpt_icon":0},{"id":"2531429967","title":"Mesoblast Appoints Corporate Finance Leader Lyn Cobley to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531429967","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531429967?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:44","pubTimestamp":1745883858,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nTUA6QPWHD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":129,"code":"91000000","status":"200"}]}}